ReviewJournal of Cancer2018
Lung Cancer and Pulmonary Embolism: What Is the Relationship? A Review.
Review in Journal of Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Clinical features of pulmonary embolism in patients with lung cancer: A meta-analysis.PloS one · 2019Pooled it
- H-X model: A novel tool for predicting pulmonary embolism in lung cancer.Chinese medical journal · 2026Article
- A case of lung cancer-associated pulmonary embolism mimicking Kimura disease: a case report.Journal of medical case reports · 2026Article
- Pulmonary Embolism in Patients with Lung Cancer: Incidence and Performance of Prognostic Markers.Cancers · 2026Article
- Article
- Incidence and Predictors of Pulmonary Embolism Recurrence and Mortality in Patients With Lung Cancers.Cureus · 2025Article
- Incidence of pulmonary embolism and its risk factors in lung cancer patients: a systematic review and meta-analysis.Discover oncology · 2025Article
- Integration of Surgical and Coagulation Risk Factors for Predicting Postoperative Pulmonary Embolism in Thoracic Surgery: A Multi-Center Retrospective Study.International journal of general medicine · 2025Article
- Genome-wide analysis of long non-coding RNAs and mRNAs in lung adenocarcinoma with pulmonary thromboembolism.Frontiers in genetics · 2025Article
- The impact of inflammatory factors on patients with concurrent lung cancer and acute pulmonary embolism.Frontiers in cardiovascular medicine · 2025Article
- Venous thromboembolism is associated with increased all-cause mortality in ALK-positive non-small cell lung cancer.Cardio-oncology (London, England) · 2024Article
- Prevalence of perioperative pulmonary embolism in patients with renal cell carcinoma undergoing nephrectomy.Heliyon · 2024Article
- Mesorectal thromboembolism with increasedJournal of surgical case reports · 2024Article
- Review
- Comparison of the efficacy and safety of rivaroxaban and low-molecular-weight heparin in Chinese lung cancer patients with nonhigh-risk pulmonary embolism.Thrombosis journal · 2023Article
- Discovery of protein biomarkers for venous thromboembolism in non-small cell lung cancer patients through data-independent acquisition mass spectrometry.Frontiers in oncology · 2023Article
- Incidence of venous thromboembolism and association with PD-L1 expression in advanced non-small cell lung cancer patients treated with first-line chemo-immunotherapy.Frontiers in oncology · 2023Article
- Unique diagnostic challenge in surgery: hepatic abscess versus malignancy.BMJ case reports · 2022Article
- Construction of Pulmonary Embolism Prediction, Early Warning, and Precontrol MDT Collaborative Nursing Model Based on the Smith Model.Computational and mathematical methods in medicine · 2022Article
- Are cardiovascular comorbidities always associated with a worse prognosis in patients with lung cancer?Frontiers in cardiovascular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary embolism (PE) is gradually considered to be the third most common disease in the vascular disease category. Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer death among males worldwide. Although initially appearing as distinct entities, lung cancer is a great risk factor for the development of PE. Pulmonary embolism is common in lung cancer patients, with a pooled incidence of 3.7%, and unsuspected pulmonary embolism (UPE) is also non-negligible with a rough rate ranging from 29.4% to 63%. Many risk factors of PE have been detected and could be classified into three categories: lung cancer-related, patient-related, and treatment-related factors. Decreased mean survival time could be significantly observed in lung cancer patients with PE or UPE compared to those only, but suspected PE has higher mortality than UPE. Prophylactic anticoagulant therapy benefit might be highest in patients with stage IV non-small cell lung cancer (NSCLC) or limited small cell lung cancer (SCLC), and heparin seems superior to warfarin for thrombotic prophylaxis. Periodically reassessing the risk-benefit ratio of anticoagulant treatment will be an efficient treatment strategy in lung cancer patients with PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.